EP2528926A1 - Composés inhibiteurs du virus de l'hépatite c - Google Patents

Composés inhibiteurs du virus de l'hépatite c

Info

Publication number
EP2528926A1
EP2528926A1 EP11736580A EP11736580A EP2528926A1 EP 2528926 A1 EP2528926 A1 EP 2528926A1 EP 11736580 A EP11736580 A EP 11736580A EP 11736580 A EP11736580 A EP 11736580A EP 2528926 A1 EP2528926 A1 EP 2528926A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
compound
pharmaceutically acceptable
added
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11736580A
Other languages
German (de)
English (en)
Other versions
EP2528926A4 (fr
Inventor
Cyrille Kuhn
Punit K . Bhardwaj
Marc-Andre Poupart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of EP2528926A1 publication Critical patent/EP2528926A1/fr
Publication of EP2528926A4 publication Critical patent/EP2528926A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I), dans laquelle R1, R2, RA, RB, Z1, Z2, Z3, Z4, Z5 et Z6 sont tels que définis ici. Lesdits composés peuvent être utilisés en tant qu'inhibiteurs de l'action de la protéine NS5A encodée par le VHC, en vue du traitement d'une infection par le virus de l'hépatite C.
EP11736580.9A 2010-01-28 2011-01-24 Composés inhibiteurs du virus de l'hépatite c Withdrawn EP2528926A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29918610P 2010-01-28 2010-01-28
US32790010P 2010-04-26 2010-04-26
PCT/CA2011/050041 WO2011091532A1 (fr) 2010-01-28 2011-01-24 Composés inhibiteurs du virus de l'hépatite c

Publications (2)

Publication Number Publication Date
EP2528926A1 true EP2528926A1 (fr) 2012-12-05
EP2528926A4 EP2528926A4 (fr) 2013-06-19

Family

ID=44318586

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11736580.9A Withdrawn EP2528926A4 (fr) 2010-01-28 2011-01-24 Composés inhibiteurs du virus de l'hépatite c

Country Status (3)

Country Link
EP (1) EP2528926A4 (fr)
JP (1) JP2013518062A (fr)
WO (1) WO2011091532A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367824B1 (fr) 2008-12-23 2016-03-23 AbbVie Inc. Dérivés de pyrimidine antiviraux
EP2367823A1 (fr) 2008-12-23 2011-09-28 Abbott Laboratories Composés antiviraux
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG175144A1 (en) 2009-04-15 2011-11-28 Abbott Lab Anti-viral compounds
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
JP5530514B2 (ja) 2009-06-11 2014-06-25 アッヴィ・バハマズ・リミテッド Ｈｃｖ感染を治療するための抗ウィルス化合物
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8835456B1 (en) 2011-03-18 2014-09-16 Achillion Pharmaceuticals, Inc. NS5A inhibitors useful for treating HCV
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
MX349079B (es) 2011-05-27 2017-07-07 Achillion Pharmaceuticals Inc Alifanos, ciclofanos, heterafanos, heterofanos, hetero-heterafanos y metalocenos sustituidos utiles para tratar infecciones por el vhc.
US8889726B2 (en) 2011-08-08 2014-11-18 Glaxosmithkline Llc Chemica compounds
TWI572587B (zh) * 2011-12-15 2017-03-01 杜邦股份有限公司 丙二酸二鹽及用以製備丙二醯基二鹵化物之方法
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN105517574B (zh) * 2013-07-09 2019-01-18 百时美施贵宝公司 丙型肝炎病毒抑制剂的组合产品
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
EP3089757A1 (fr) 2014-01-03 2016-11-09 AbbVie Inc. Formes galéniques antivirales solides
CN104478877B (zh) * 2014-10-31 2016-08-24 广东东阳光药业有限公司 制备雷迪帕韦中间体的方法
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10487067B2 (en) * 2015-10-08 2019-11-26 Mylan Laboratories Limited Process for the preparation of velpatasvir
CN105732563B (zh) * 2016-03-23 2018-08-28 江苏苏利精细化工股份有限公司 一种合成9-溴-3-(2-溴乙酰基)-10，11-二氢-5H-二苯并[c,g]色烯-8(9h)-酮的新方法
CN106966914B (zh) * 2017-05-04 2019-02-22 无锡捷化医药科技有限公司 一种5-溴-4-氯-2-氨基苯乙酮的制备方法
CN108753863A (zh) * 2018-06-14 2018-11-06 慎终（上海）生物科技有限公司 雷迪帕韦中间体的合成工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031904A1 (fr) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Inhibiteurs du virus de l'hépatite c

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RS55249B8 (sr) * 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031904A1 (fr) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Inhibiteurs du virus de l'hépatite c

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011091532A1 *

Also Published As

Publication number Publication date
WO2011091532A1 (fr) 2011-08-04
EP2528926A4 (fr) 2013-06-19
JP2013518062A (ja) 2013-05-20

Similar Documents

Publication Publication Date Title
WO2011091532A1 (fr) Composés inhibiteurs du virus de l'hépatite c
WO2012048421A1 (fr) Composés inhibiteurs de l'hépatite c
EP2430015B1 (fr) Composés aryles tricycliques condensés utiles pour le traitement de maladies virales
JP5762971B2 (ja) Ｈｃｖｎｓ５ａの阻害剤
TWI494309B (zh) Ｃ型肝炎病毒（ｈｃｖ）nｓ５ａ抑制劑
CA2615921C (fr) Analogues de peptides inhibiteurs de l'hepatite c comprenant une partie de quinoleine ou de thienopyridine
EP2435424B1 (fr) Composés antiviraux de trois fractions d'aryle liées pour traiter des maladies telles que l'hépatite c
JP5735482B2 (ja) 縮合環のｃ型肝炎阻害剤
WO2012019299A1 (fr) Composés inhibiteurs de l'hépatite c
WO2012040389A2 (fr) Inhibiteurs bicycliques substitués du virus de l'hépatite c
EP2575866A1 (fr) Inhibiteurs de ns5a du vhc
US20120077737A1 (en) Hepatitis c inhibitor compounds
EP2575475A1 (fr) Inhibiteurs de ns5a de vhc
AU2005263135A1 (en) Viral polymerase inhibitors
EP1730167A1 (fr) Peptides macrocycliques actifs contre le virus de l'hepatite c
WO2011063502A1 (fr) Composés inhibiteurs de l'hépatite c
EP3063149A1 (fr) Inhibiteurs du virus syncytial respiratoire à base de quinazoline
EP2914598B1 (fr) Inhibiteurs du virus de l'hépatite c
KR20140145126A (ko) Hcv ns5a의 저해제를 포함하는 고체형태, 이의 조성물 및 이에 의한 용도
US9340539B2 (en) Hepatitis C inhibitor compounds
WO2015065336A1 (fr) Inhibiteurs du virus respiratoire syncytial
US9340548B2 (en) Substituted pyrazolo[3,4-a]carbazoles as hepatitis C inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120828

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130523

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/14 20060101ALI20130516BHEP

Ipc: C07D 519/00 20060101AFI20130516BHEP

Ipc: A61K 31/444 20060101ALI20130516BHEP

Ipc: A61K 31/439 20060101ALI20130516BHEP

Ipc: A61K 31/506 20060101ALI20130516BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130801